Improving API Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving API Synthesis
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 52-56

References

1. N. Yoshikawa et al., Org. Process. Res. Dev. 15 (4), 824–830 (2011).

2. K. Mandal and S.B.H. Kent, Total Chemical Synthesis of Biologically Active Vascular Endothelial Growth Factor Agnew. Chem. Int. Ed, online, DOI 10.1002/anie.201103237, July 8, 2011.

3. L.K. Wolf, Chem. & Eng. News 89 (29), 27–28 (2011).

4. T. Noel et al., Suzuki–Miyaura Cross-Coupling Reactions in Flow: Multistep Synthesis Enabled by a Microfluidic Extraction, Agnew. Chem. Int. Ed. online, DOI: 10.1002/anie.201101480, May 17, 2011.

5. S.R. Ritter, Chem. & Eng. News 89 (23), 39 (2011).

6. P. Van Arnum, Pharm. Technol . 34 (12) 40–42 (2010).

7. N. Korman et al., API Synthesis, Formulation Development, and Manufacturing, asupplement to Pharm. Technol., s32–s36 (2010).

8. P. Li and S. L. Buchwald, Continuous-Flow Synthesis of 3,3-Disubstituted Oxindoles by a Palladium-Catalyzed a-Arylation/Alkylation Sequence, Agnew. Chem. Int. Ed. online, DOI: 10.1002/anie.201102401, June 7, 2011.

9. J.P. McMullen and K.F. Jensen, Org. Process Res. Dev. 14 (5), 1169–1176 (2010).

10. K.F. Jensen et al., Ind. Eng. Chem. Res. 49 (22), 11310–11320 (2010).

11. EPA, Presidential Green Chemistry Challenge Awards Program: Summary of 2011 Award Entries and Recipients (Washington, DC, June 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here